Cerveau to develop Merck imaging agent for Alzheimer's Tau tangles

By Dani Bancroft contact

- Last updated on GMT

Cerveau to develop Merck imaging agent for Alzheimer’s Tau tangles

Related tags: Positron emission tomography, Alzheimer's disease

In an exclusive licensing agreement with Merck & Co Inc (MSD), Cerveau will take on development of the firm’s investigative PET imaging agent up to Phase III trials for Alzheimer’s Disease.

Cerveau Technologies Inc is a US clinical research organisation (CRO) which specialises in molecular imaging.

The Boston-based firm is the result of a partnership betwen Enigma Biomedical Group Inc in France and Sinotau Pharmaceutical Group in China.

With Alzheimer’s disease, an abnormal version of the Tau protein accumulates in the brain to form aggregates called neurofibrillary tangles.

Merck’s investigational agent – MK6240 – is being developed to image these Tau tangles using Positron Emission Tomography​ (PET) scanning.

A preclinical study​ of MK6240 reported the imaging agent works well in selecting and binding to neurofibrillary tangles, with Merck and Cerveau currently running a Phase I open-label trial​ scheduled to end this month.

Now, Cerveau has decided to fully license MK6240 for clinical development and commercialisation, announcing plans for a Phase III programme in 2018.

“There is a critical need for sensitive biomarkers for diagnosis and monitoring of tau pathology in neurodegenerative diseases,”​ said Darryle Schoepp VP of discovery at Merck Research Laboratories.

“[This is] to allow for more appropriate staging of disease states, and measuring the effect of candidate disease-modifying therapeutics.”

Merck will receive license fees, milestone payments and royalties on worldwide sales.

Feature Image: iStock/HASLOO

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more